Evidence map›Paper›PMID 35886898›Full record

ArticleInternational journal of molecular sciences2022

Non-Functionalized Gold Nanoparticles Inhibit Human Papillomavirus (HPV) Infection.

Diana Gabriela Valencia-Reséndiz, Atenea Villegas, Daniel Bahena, Kenia Palomino, Jose Manuel Cornejo-Bravo, Liliana Quintanar, Giovanni Palomino-Vizcaino, Luis Marat Alvarez-Salas

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. HPV Infections-Classification, Pathogenesis, and Potential New Therapies.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Diana Gabriela Valencia-ReséndizLaboratorio de Terapia Génica, Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del I.P.N., Av. Instituto Politécnico Nacional 2508, Ciudad de México 07360, Mexico.
Atenea VillegasDepartamento de Química, Centro de Investigación y de Estudios Avanzados del I.P.N., Av. Instituto Politécnico Nacional 2508, Ciudad de México 07360, Mexico.
Daniel BahenaLaboratorio Avanzado de Nanoscopía Electrónica (LANE), Centro de Investigación y de Estudios Avanzados del I.P.N., Av. Instituto Politécnico Nacional 2508, Ciudad de México 07360, Mexico.
Kenia PalominoLaboratorio de Biofarmacia, Faculta de Ciencias Químicas e Ingeniería, Universidad Autónoma de Baja California, Calzada Universidad 14418, Col. Parque Industrial Internacional, Tijuana 22424, Mexico.
Jose Manuel Cornejo-BravoLaboratorio de Biofarmacia, Faculta de Ciencias Químicas e Ingeniería, Universidad Autónoma de Baja California, Calzada Universidad 14418, Col. Parque Industrial Internacional, Tijuana 22424, Mexico.ORCID 0000-0002-0013-8937
Liliana QuintanarDepartamento de Química, Centro de Investigación y de Estudios Avanzados del I.P.N., Av. Instituto Politécnico Nacional 2508, Ciudad de México 07360, Mexico.ORCID 0000-0003-3090-7175
Giovanni Palomino-VizcainoFacultad de Ciencias de la Salud, Unidad Valle de las Palmas, Campus Tijuana, Universidad Autónoma de Baja California, Boulevard Universitario 1000, Valle de las Palmas, Tijuana 21500, Mexico.ORCID 0000-0001-8905-7377
Luis Marat Alvarez-SalasLaboratorio de Terapia Génica, Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del I.P.N., Av. Instituto Politécnico Nacional 2508, Ciudad de México 07360, Mexico.ORCID 0000-0002-3646-3723
Instituto Politécnico Nacional · MXUniversidad Autónoma de Baja California · MX

Funding

Consejo Nacional de Ciencia y Tecnología A1-S-9160Consejo Nacional de Ciencia y Tecnología PEI222162
6 · The paper itself

Abstract

The spontaneous interaction between human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) and non-functionalized gold nanoparticles (nfGNPs) interferes with the nfGNPs' salt-induced aggregation, inhibiting the red-blue color shift in the presence of NaCl. Electron microscopy and competition studies showed that color-shift inhibition is a consequence of direct nfGNP-VLP interaction and, thus, may produce a negative impact on the virus entry cell process. Here, an in vitro infection system based on the HPV16 pseudovirus (PsV) was used to stimulate the natural infection process in vitro. PsVs carry a pseudogenome with a reporter gene, resulting in a fluorescent signal when PsVs infect a cell, allowing quantification of the viral infection process. Aggregation assays showed that nfGNP-treated PsVs also inhibit color shift in the presence of NaCl. High-resolution microscopy confirmed nfGNP-PsV complex formation. In addition, PsVs can interact with silver nanoparticles, suggesting a generalized interaction of metallic nanoparticles with HPV16 capsids. The treatment of PsVs with nfGNPs produced viral infection inhibition at a higher level than heparin, the canonical inhibitor of HPV infection. Thus, nfGNPs can efficiently interfere with the HPV16 cell entry process and may represent a potential active component in prophylactic formulations to reduce the risk of HPV infection.

Indexed as

Metal NanoparticlesOncogene Proteins, ViralPapillomavirus InfectionsCapsid ProteinsGoldHuman papillomavirus 16HumansSilverSodium ChlorideCapsid ProteinsGoldOncogene Proteins, ViralSilverSodium Chloridegold nanoparticlesHPVhuman papillomavirusnanocomplex formationnanoprophylaxispseudovirusviral infection inhibitionviral inhibition

Identifiers

PMID35886898
PMCPMC9318239
OpenAlexW4284892948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.